Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adherence to Lumacaftor/Ivacaftor in CF
NCT02823470Phase 4Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Aug 2017
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Percentage Adherence to Lumacaftor/Ivacaftor (LUM/IVA) Treatment at 35 weeks. Started Jun 2016; status: terminated.
Beyond the preview
Go deeper on NCT02823470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02823470.